SNN Stock Might Rise Following FDA Nod for AETOS Stemless
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine.
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
Smith & Nephew Delivering On Its Turnaround Promise
The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to grow, SNN has continued to lose share in major joints and this is the biggest item on management's to-do list now. Management has identified additional savings opportunities that will help boost margins further, and coupled with improved sales execution, could drive EBITDA to 30% over the next five years.
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
